Using Cotyledon Perfusion to Study Drugs Transfer Across the Placenta

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorAssistance Publique - Hôpitaux de Paris

About this trial

Drug prescriptions are usual during pregnancy however women and their fetuses still remain an orphan population with regard to drugs efficacy and safety clinical studies. Most xenobiotics diffuse through the placenta and some of them can alter fetus development resulting in structural abnormalities, growth or functional deficiencies. The aim of the study is to study the drug transfer using human placenta after delivery.

Eligibility criteria

Qualifiers

pregnant women older than 18 years,

patient with social security or health insurance,

from the 24th week of amenorrhea,

patient who has given her consent,

Disqualifiers

diabetes-like vascular disease,

arterial hypertension,

known prothrombotic pathology, history of venous thrombosis or pulmonary embolism,

maternal serology HIV+, BHV+, CHV+ and syphilis,

Trial design

Treatments tested in this trial

  • Placenta perfusion

Treatment groups

2,000 Participants
are divided into 1 treatment group

Sponsors and collaborators

Assistance Publique - Hôpitaux de Paris

Lead sponsor

URC-CIC Paris Descartes Necker Cochin

Collaborator